Development of an MRI contrast agent for both detection and inhibition of the amyloid-β fibrillation process

Rohmad Yudi Utomo,Akira Sumiyoshi,Hiroyuki Nakamura,Satoshi Okada,Ichio Aoki

doi:10.1039/d2ra00614f

Abstract

A curcumin derivative conjugated with Gd-DO3A (Gd-DO3A-Comp.B) was synthesised as an MRI contrast agent for detecting the amyloid-β (Aβ) fibrillation process. Gd-DO3A-Comp.B inhibited Aβ aggregation significantly and detected the fibril growth at 20 μM of Aβ with 10 μM of probe concentration by T1-weighted MR imaging.

Highlights

A curcumin derivative conjugated with Gd-DO3A (Gd-DO3A-Comp.B) was synthesised as an magnetic resonance imaging (MRI) contrast agent for detecting the amyloid-b (Ab) fibrillation process
positron emission tomography (PET)- and single photon emission computed tomography (SPECT)-based diagnostics require injection of radioactive probes, which cannot be measured frequently due to radiation exposure and limited availability of facilities
These previous studies demonstrate that the curcumin structure has signi cant potential for the development of MRI contrast agents for Alzheimer's disease (AD) diagnosis

Summary

Introduction

A curcumin derivative conjugated with Gd-DO3A (Gd-DO3A-Comp.B) was synthesised as an MRI contrast agent for detecting the amyloid-b (Ab) fibrillation process. Gd-DO3A-Comp.B inhibited Ab aggregation significantly and detected the fibril growth at 20 mM of Ab with 10 mM of probe concentration by T1weighted MR imaging.

Results

Conclusion